RESUMEN
Although acanthosis nigricans of the posterior neck and intertriginous areas is common, acanthosis nigricans of the supra-alar creases is rare. We present the case of an obese 16-year-old African American boy with hyperpigmented plaques along the supra-alar creases of his nose. Clinicians should be aware of this rare manifestation, because newly diagnosed acanthosis nigricans should prompt examination for insulin resistance.
Asunto(s)
Acantosis Nigricans/patología , Nariz/patología , Adolescente , Humanos , MasculinoRESUMEN
A number of cutaneous disorders encountered by the dermatologist have overlapping cardiac pathology. In recent years, many genetic linkages common to pathological processes in the cutaneous and cardiovascular systems have been identified. This review will describe primary cutaneous disorders with potential cardiac manifestations, including congenital syndromes, inherited cutaneous disorders associated with later cardiovascular disease, and syndromes associated with early cardiovascular pathology. The dermatologist may be the first to diagnose cutaneous findings associated with underlying cardiovascular disease; therefore, it is of prime importance for the dermatologist to be aware of these associations and to direct the appropriate workup.
Asunto(s)
Enfermedades Cardiovasculares/congénito , Enfermedades Cardiovasculares/genética , Enfermedades de la Piel/congénito , Enfermedades de la Piel/genética , Enfermedades Cardiovasculares/complicaciones , Humanos , Sistema de Señalización de MAP Quinasas , Enfermedades de la Piel/complicacionesRESUMEN
BACKGROUND: Many factors, including patients' methods of payment, may influence psoriasis treatment decisions. OBJECTIVE: To characterize psoriasis treatments by patients' types of payment in the US outpatient office setting. METHODS: Using the National Ambulatory Medical Care Survey (NAMCS), a large survey that samples outpatient office visits to US non-federally funded physicians, visits linked with sole diagnoses for psoriasis (ICD-9-CM: 696.1) were identified. There were 545 unweighted records. The types and number of treatments prescribed at these visits were categorized by expected major payment type to be used for the visit. RESULTS: Mainstay psoriasis therapies such as vitamin D analogs and clobetasol were prescribed regardless of payment type. Retinoids were also within the most frequently prescribed psoriasis medications for all payment types, however they were less frequently prescribed than vitamin D analogs. Payment type did not have a significant effect on the number of medications prescribed at psoriasis visits. LIMITATIONS: Data on treatment adherence and filling of prescriptions are not included in the NAMCS database. CONCLUSION: Prescribing patterns for psoriasis medications are similar across payment type. Additional factors appear to modulate therapy choice for patients with psoriasis.
Asunto(s)
Psoriasis/tratamiento farmacológico , Psoriasis/economía , Administración Tópica , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Clobetasol/uso terapéutico , Utilización de Medicamentos/estadística & datos numéricos , Encuestas de Atención de la Salud , Humanos , Seguro de Salud , Masculino , Medicaid , Medicare , Persona de Mediana Edad , Pacientes Ambulatorios , Psoriasis/epidemiología , Retinoides/uso terapéutico , Triamcinolona Acetonida/uso terapéutico , Estados Unidos/epidemiología , Vitamina D/análogos & derivados , Vitamina D/uso terapéutico , Vitaminas/uso terapéutico , Adulto JovenRESUMEN
Background The chronic and relapsing course of psoriasis is often associated with poor adherence to treatment. Adherence to topical treatment is abysmal. Adherence to systemic treatments also decreases over time, with an overall adherence rate of 67% for injectable biologic medications. Whereas overall trends in poor adherence have been documented, the fine details of adherence in individual patients is not well characterized. Purpose To assess adherence to adalimumab in patients with moderate to severe psoriasis. Methods Data on adherence were obtained from a 1-year open label trial including seven patients with moderate to severe psoriasis who agreed to participate in a randomized trial of standard physician education materials plus extended nurse education versus standard physician education materials alone. Adherence to treatment was recorded with electronic monitoring via Medication Event Monitoring System (MEMS) caps undisclosed to the patients. Patients were also instructed to note the time and date they used treatment in a journal. Results The subjects exhibited a broad range of adherence behaviors. Conclusions Adherence to adalimumab therapy for moderate-to-severe psoriasis is variable and can be very poor. The clinical impact of poor adherence to injectable biologic medications is not yet well characterized.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Productos Biológicos/uso terapéutico , Cumplimiento de la Medicación , Psoriasis/tratamiento farmacológico , Adalimumab , Anticuerpos Monoclonales Humanizados/administración & dosificación , Productos Biológicos/administración & dosificación , Esquema de Medicación , Monitoreo de Drogas/instrumentación , Humanos , Inyecciones Subcutáneas , Registros Médicos , Eliminación de Residuos Sanitarios/instrumentación , Agujas , Educación del Paciente como Asunto/métodos , Psoriasis/psicología , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricosRESUMEN
BACKGROUND: Some dermatologic disorders are known to be much more common in patients of color, but the leading dermatologic disorders in patients of color have not yet been described on the basis of nationally representative data. PURPOSE: To determine the leading dermatologic disorders for each major racial and ethnic group in the United States. METHODS: We queried the National Ambulatory Medical Care Survey (NAMCS) for the leading diagnoses in patient visits to U.S. dermatologists from 1993 to 2009. The leading diagnoses were tabulated for each racial and ethnic group, and the top conditions were compared between groups. In a separate analysis, visits for skin conditions regardless of physician specialty were analyzed for leading diagnoses in each racial and ethnic group. RESULTS: The top five diagnoses for African-American patients in dermatology clinics were acne, unspecified dermatitis or eczema, seborrheic dermatitis, atopic dermatitis, and dyschromia. For Asian or Pacific Islander patients, the top five were acne, unspecified dermatitis or eczema, benign neoplasm of skin, psoriasis, and seborrheic keratosis. By contrast, in Caucasian patients, the top five were actinic keratosis, acne, benign neoplasm of skin, unspecified dermatitis or eczema, and nonmelanoma skin cancer. In Hispanic patients of any race, the leading diagnoses were acne, unspecified dermatitis or eczema, psoriasis, benign neoplasm of skin, and viral warts. When the leading dermatologic diagnoses across all physician specialties were assessed, the top diagnoses for African-Americans were unspecified dermatitis or eczema, acne, dermatophytosis of scalp and beard, sebaceous cyst, and cellulitis or abscess; for Asians or Pacific Islanders were unspecified dermatitis or eczema, acne, atopic dermatitis, urticaria, and psoriasis; and for Caucasians were acne, unspecified dermatitis or eczema, actinic keratosis, viral warts, and sebaceous cyst. For Hispanics of any race, they were unspecified dermatitis or eczema, acne, sebaceous cyst, viral warts, and cellulitis or abscess. For a sole diagnosis of a dermatologic condition, only 28.5% of African-Americans' visits and 23.9% of Hispanics' visits were to dermatologists, as compared to 36.7% for Asians and Pacific Islanders and 43.2% for Caucasians. LIMITATIONS: The data are based on numbers of ambulatory care visits rather than numbers of patients. Data on race or ethnicity were not collected for some patients. CONCLUSIONS: Several dermatologic disorders are much more commonly seen in patients of color. Acne and unspecified dermatitis or eczema are in the top five for all major U.S. racial and ethnic groups. There may be an opportunity to improve the care of patients of color by ensuring they have equal access to dermatologists.
Asunto(s)
Etnicidad/estadística & datos numéricos , Grupos Raciales/estadística & datos numéricos , Enfermedades de la Piel/epidemiología , Pigmentación de la Piel , Atención Ambulatoria/estadística & datos numéricos , Encuestas de Atención de la Salud , Humanos , Enfermedades de la Piel/etnología , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Nevus sebaceus of Jadassohn is a complex congenital hamartoma that has a predominant sebaceous component. It presents as waxy, well-circumscribed, yellow plaques localized to the head and neck. Its genetic etiology has more often been described as sporadic, with scattered cases featuring autosomal dominant transmission also reported. The development of benign tumors within the lesions is a well-known phenomenon and requires clinical surveillance for new growths suggesting malignant transformation. MAIN OBSERVATIONS: We report three cases of nevus sebaceus of Jadassohn localized to the scalp in a mother and her two daughters. CONCLUSIONS: This case further supports the underlying genetic association in familial cases of NSJ, specifically autosomal dominant transmission.
Asunto(s)
Nevo Sebáceo de Jadassohn/genética , Dermatosis del Cuero Cabelludo/genética , Niño , Femenino , Humanos , Nevo Sebáceo de Jadassohn/patología , Dermatosis del Cuero Cabelludo/patologíaRESUMEN
INTRODUCTION: Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne. AREAS COVERED: Tazarotene is a topical retinoid available as a cream, gel and foam. Tazarotene 0.1% foam was FDA approved in 2012 for the treatment of acne in patients ages ≥12 and is the first foam topical retinoid on the market. Phase I and III trials support the efficacy and safety of tazarotene foam for acne. EXPERT OPINION: The foam vehicles may increase compliance and satisfaction in some patients and as retinoids are commonly first line acne treatments, this new topical retinoid foam may be a useful option for some acne patients.